Abbott Laboratories (ABT) Free Cash Flow (2009 - 2026)

Abbott Laboratories has disclosed Free Cash Flow across 18 years of filings, most recently posting $2.0 billion for Q2 2026.

• In Q2 2026, Free Cash Flow rose 28.87% year-over-year to $2.0 billion; the TTM figure through Jun 2026 stood at $7.8 billion (up 15.48% YoY), while the FY2025 annual figure was $7.4 billion, up 16.44% from the prior year.
• Free Cash Flow came in at $2.0 billion for Q2 2026 at Abbott Laboratories, up from $916.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $2.6 billion in Q4 2025 to a low of $627.0 million in Q1 2024.
• Average Free Cash Flow over 5 years is $1.6 billion, with a median of $1.7 billion recorded in 2022.
• Year-over-year, Free Cash Flow slumped 65.73% in 2023 and surged 105.03% in 2024.
• Over 5 years, Free Cash Flow stood at $1.7 billion in 2022, then surged by 33.04% to $2.3 billion in 2023, then dropped by 5.91% to $2.1 billion in 2024, then gained by 22.25% to $2.6 billion in 2025, then fell by 24.18% to $2.0 billion in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $2.0 billion in Q2 2026, $916.0 million in Q1 2026, and $2.6 billion in Q4 2025.